PDCD1 and brain neoplasm: More recent research has demonstrated that immunotherapy options, such as Programmed Cell Death Protein-1 (PD-1) or Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) inhibition, may prove useful for treating brain tumors [6, 7], but these have not yet succeeded in phase 3 clinical trials [8].